Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls
Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls
复制标题
DOI：
10.14309/ajg.0000000000001570
复制
发表时间：
2022-01-01
影响因子：
9.8
通讯作者：
Farraye, Francis A.
中科院分区：
文献类型：
--
作者：
Caldera, Freddy;Knutson, Keith L.;Farraye, Francis A.
前言：使用免疫调节疗法的炎症性肠病(IBD)患者对某些疫苗的疫苗反应率可能较低。本研究的目的是评价新冠肺炎疫苗在IBD患者和健康对照组中的体液免疫原性。方法：我们进行了一项前瞻性研究，以评估新冠肺炎基因疫苗完成后IBD和HCS患者的体液免疫原性。结果：入选IBD患者122例，肥厚型肝炎患者60例。所有HCS和97%的IBD患者都产生了抗体。炎症性肠病患者的抗体浓度低于肝细胞癌患者(中位数为31vs118mUg/mL；P<；0.001)。与接受辉瑞-BNT系列疫苗接种的患者(中位数22；四分位数范围11-42mU g/mL；P<；0.001)相比，接种新冠肺炎(中位数38；四分位数范围[IQR]24-75vsu g/ml)的患者抗体浓度更高。接受免疫调节治疗的患者(中位数26；IQR13~50mUg/mL)的抗体浓度低于未接受治疗、氨基水杨酸酯或维多利单抗的患者(中位数59；IQR31~75mUg/mL；P=0.003)。讨论：在我们的研究中，几乎所有的IBD患者都有抗体反应。在评估IBD患者的持续体液免疫和加强剂量的影响方面，还需要进一步的研究。
INTRODUCTION: Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs). METHODS: We performed a prospective study to evaluate humoral immunogenicity among patients with IBD and HCs after completion of mRNA COVID-19 vaccines. RESULTS: One hundred twenty-two patients with IBD and 60 HCs were enrolled. All HCs and 97% of patients with IBD developed antibodies. Antibody concentrations were lower in patients with IBD compared with those in HCs (median 31 vs 118 mu g/mL; P < 0.001). Those who received the mRNA-1273 (Moderna) COVID-19 (median 38; interquartile range [IQR] 24-75 vs mu g/mL) had higher antibody concentrations compared with those who received the Pfizer-BNT vaccine series (median 22; IQR 11-42 mu g/mL; P < 0.001). Patients on immune-modifying therapy (median 26; IQR 13-50 mu g/mL) had lower antibody concentrations compared with those who were on no treatment, aminosalicylates, or vedolizumab (median 59; IQR 31-75 mu g/mL; P = 0.003). DISCUSSION: Almost all patients with IBD in our study mounted an antibody response. Future studies are needed in evaluating sustained humoral immunity and the impact of booster dosing in patients with IBD.